Factor V Leiden and the risk for venous thromboembolism in the adult Danish population
- PMID: 14996674
- DOI: 10.7326/0003-4819-140-5-200403020-00008
Factor V Leiden and the risk for venous thromboembolism in the adult Danish population
Abstract
Background: Odds ratios for venous thromboembolism (deep venous thrombosis and pulmonary embolism) derived from case-control studies range from 3 to 16 for heterozygotes compared with noncarriers and up to 79 for homozygotes compared with noncarriers.
Objective: To estimate risks for venous thromboembolism in the adult Danish population according to factor V Leiden genotype.
Design: Cohort study with 23 years of follow-up.
Setting: Adult Danish population.
Participants: 9253 randomly selected individuals.
Measurements: Hospitalization and death from venous thromboembolism, factor V Leiden genotype, and additional thromboembolic risk factors.
Results: Adjusted hazard ratios in heterozygotes and homozygotes compared with noncarriers were 2.7 (95% CI, 1.8 to 3.8) and 18 (CI, 4.1 to 41) for venous thromboembolism overall, 2.4 (CI, 1.3 to 3.8) and 22 (CI, 0 to 60) for deep venous thrombosis, and 3.0 (CI, 1.7 to 4.9) and 11 (CI, 0 to 33) for pulmonary embolism. The lowest absolute 10-year risks for venous thromboembolism in factor V Leiden heterozygotes and homozygotes--0.7% (CI, 0.5% to 1.0%) and 3% (CI, 1% to 8%)--were found in nonsmokers younger than 40 years of age with a body mass index below 25 kg/m2; the corresponding highest risks--10% (CI, 7% to 14%) and 51% (CI, 13% to 100%)--were found in smokers older than 60 years of age with a body mass index above 30 kg/m2.
Conclusions: Hazard ratios for venous thromboembolism in factor V Leiden heterozygotes and homozygotes compared with noncarriers in the adult Danish population were approximately 3 and 18, respectively. The simultaneous presence of smoking, obesity, and old age resulted in absolute 10-year thromboembolic risks of 10% in heterozygotes and 51% in homozygotes.
Comment in
-
Summaries for patients. Blood clots in people with factor V Leiden mutation.Ann Intern Med. 2004 Mar 2;140(5):I50. doi: 10.7326/0003-4819-140-5-200403020-00002. Ann Intern Med. 2004. PMID: 14996692 No abstract available.
-
Factor V Leiden and venous thromboembolism.Ann Intern Med. 2004 Sep 21;141(6):483-4. doi: 10.7326/0003-4819-141-6-200409210-00023. Ann Intern Med. 2004. PMID: 15381529 No abstract available.
-
Factor V Leiden and venous thromboembolism.Ann Intern Med. 2004 Sep 21;141(6):484. doi: 10.7326/0003-4819-141-6-200409210-00024. Ann Intern Med. 2004. PMID: 15381530 No abstract available.
Similar articles
-
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.Ann Intern Med. 2001 Sep 4;135(5):322-7. doi: 10.7326/0003-4819-135-5-200109040-00008. Ann Intern Med. 2001. PMID: 11529695
-
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.Thromb Haemost. 2001 Sep;86(3):809-16. Thromb Haemost. 2001. PMID: 11583312
-
Summaries for patients. Blood clots in people with factor V Leiden mutation.Ann Intern Med. 2004 Mar 2;140(5):I50. doi: 10.7326/0003-4819-140-5-200403020-00002. Ann Intern Med. 2004. PMID: 14996692 No abstract available.
-
Contraception-related deep venous thrombosis and pulmonary embolism in a 17-Year-old girl heterozygous for factor V leiden, prothrombin G20210A mutation, MTHFR C677T and homozygous for PAI-1 mutation: report of a family with multiple genetic risk factors and review of the literature.Pathophysiol Haemost Thromb. 2010;37(1):24-9. doi: 10.1159/000319051. Epub 2010 Jul 20. Pathophysiol Haemost Thromb. 2010. PMID: 20664190 Review.
-
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.Ann Intern Med. 1997 Nov 15;127(10):895-903. doi: 10.7326/0003-4819-127-10-199711150-00007. Ann Intern Med. 1997. PMID: 9382368 Review.
Cited by
-
Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.Thromb J. 2024 Apr 4;22(1):34. doi: 10.1186/s12959-024-00599-3. Thromb J. 2024. PMID: 38576023 Free PMC article. Review.
-
High prevalence of thrombophilic risk factors in patients with central retinal artery occlusion.Thromb J. 2023 Jul 28;21(1):81. doi: 10.1186/s12959-023-00525-z. Thromb J. 2023. PMID: 37507715 Free PMC article.
-
A Study on the Distinctive Clinical Profile and Thrombophilia in Pediatric Cerebral Venous Sinus Thrombosis.J Pediatr Neurosci. 2021 Jul-Sep;16(3):225-231. doi: 10.4103/jpn.JPN_121_20. Epub 2021 Jul 2. J Pediatr Neurosci. 2021. PMID: 36160607 Free PMC article.
-
Association between cardiovascular risk factors and venous thromboembolism in the elderly.Res Pract Thromb Haemost. 2022 Mar 1;6(2):e12671. doi: 10.1002/rth2.12671. eCollection 2022 Feb. Res Pract Thromb Haemost. 2022. PMID: 35252737 Free PMC article.
-
The Higher Prevalence of Venous Thromboembolism in the Hungarian Roma Population Could Be Due to Elevated Genetic Risk and Stronger Gene-Environmental Interactions.Front Cardiovasc Med. 2021 Oct 26;8:647416. doi: 10.3389/fcvm.2021.647416. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34765649 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
